Sangam Health Care Products reports a steep fall in net profit to Rs 5.33 lakh for FY 2025-26, alongside ongoing BSE trading suspension. Investors face significant risks from pending compliance requirements and governance gaps identified in the latest secretarial audit.
Sangam Health Care Reports Profit Decline Amid Trading Suspension
Profit After Tax dropped to Rs 5.33 lakh in FY 2025-26, down from Rs 44.97 lakh in FY 2024-25.
Total Income declined to Rs 1123.33 lakh from Rs 1245.96 lakh in the previous fiscal year.
Reader Takeaway: Sharp profit contraction and multiple secretarial audit failures create significant uncertainty for long-term shareholder value.
What just happened
Sangam Health Care Products Ltd has released its financial performance for FY 2025-26, coinciding with preparations for its 32nd Annual General Meeting scheduled for September 30, 2026. The company remains under suspension on the BSE platform, with management actively engaged in efforts to clear regulatory hurdles for trading revocation.
Why this matters
The company reported a significant earnings compression, with profits plummeting over 88% year-on-year. Furthermore, the Secretarial Audit Report highlights 10 critical non-compliances. These include failures to publish timely financial results, absence of director independence declarations, and a lapse in conducting mandatory annual board evaluations. The auditor also flagged the company's failure to maintain essential statutory registers and produce board meeting records.
Governance Update
The Board of Directors has proposed the re-appointment of Mr. Bhagat Reddy Dundumulla as Managing Director for a five-year term beginning September 7, 2026. Management has attributed the compliance lapses to financial constraints and internal procedural oversights, committing to stricter regulatory adherence moving forward. No dividend has been recommended for the fiscal year.
Risks to watch
The primary risk remains the ongoing BSE suspension. Without rectifying the long list of audit qualifications and improving operational transparency, the company may face further regulatory scrutiny. Investors should monitor the outcome of the upcoming AGM regarding the re-appointment of leadership and the roadmap for clearing pending compliance gaps.
What to track next
Watch for developments regarding the BSE suspension revocation process and any official updates on the resolution of the secretarial audit findings.